Search

Your search keyword '"Lundy, Scott D."' showing total 260 results
Start Over Author "Lundy, Scott D."
260 results on '"Lundy, Scott D."'

4. The Deafening Silence of Male Infertility

Author

Nam, Catherine S, Campbell, Kevin J, Acquati, Chiara, Bole, Raevti, Adler, Ava, Collins, David J, Collins, Erica, Samplaski, Mary, Anderson-Bialis, Jake, Andino, Juan J, Asafu-Adjei, Denise, Gaskins, Audrey J, Bortoletto, Pietro, Vij, Sarah C, Orwig, Kyle E, and Lundy, Scott D

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Infertility, Contraception/Reproduction, Reproductive health and childbirth, Clinical Sciences, Urology & Nephrology, Clinical sciences
Published
2023

9. Deafening Silence of Male Infertility

Author

Nam, Catherine S., Campbell, Kevin J., Acquati, Chiara, Bole, Raevti, Adler, Ava, Collins, David J., Collins, Erica, Samplaski, Mary, Anderson-Bialis, Jake, Andino, Juan J., Asafu-Adjei, Denise, Gaskins, Audrey J., Bortoletto, Pietro, Vij, Sarah C., Orwig, Kyle E., and Lundy, Scott D.

Published
2023
Full Text
View/download PDF

15. Elevated periprostatic venous testosterone correlates with prostate cancer progression after radical prostatectomy

Author

Alyamani, Mohammad, Michael, Patrick, Hettel, Daniel, Thomas, Lewis, Lundy, Scott D., Berk, Mike, Patel, Mona, Li, Jianbo, Rashidi, Hooman, McKenney, Jesse K., Klein, Eric A., and Sharifi, Nima

Subjects
Prostate cancer -- Development and progression -- Prognosis -- Care and treatment -- Patient outcomes, Prostatectomy -- Patient outcomes, Testosterone -- Measurement -- Health aspects, Health care industry
Abstract

BACKGROUND. Generally, clinical assessment of gonadal testosterone (T) in human physiology is determined using concentrations measured in peripheral blood. Prostatic T exposure is similarly thought to be determined from peripheral T exposure. Despite the fact that androgens drive prostate cancer, peripheral T has had no role in the clinical evaluation or treatment of men with localized prostate cancer. METHODS. To assess the role of local androgen delivery in prostate cancer, we obtained blood from the (periprostatic) prostatic dorsal venous complex in 266 men undergoing radical prostatectomy from July 2014 to August 2021 and compared dorsal T (DT) levels with those in circulating peripheral blood (PT) and prostatic tissue. Comprehensive targeted steroid analysis and unbiased metabolomics analyses were performed. The association between the DT/PT ratio and progression-free survival after prostatectomy was assessed. RESULTS. Surprisingly, in some men, DT levels were enriched several-fold compared with PT levels. For example, 20% of men had local T concentrations that were at least 2-fold higherthan peripheral T concentrations. Isocaproic acid, a byproduct of androgen biosynthesis, and 17-OH-progesterone, a marker of intratesticular T, were also enriched in the dorsal vein of these men, consistent with testicular shunting. Men with enriched DT had higher rates of prostate cancer recurrence. DT/PT concentration ratios predicted worse outcomes even when accounting for known clinical predictors. CONCLUSIONS. These data suggest that a large proportion of men have a previously unappreciated exposure to an undiluted and highly concentrated T supply. Elevated periprostatic T exposure was associated with worse clinical outcomes after radical prostatectomy. FUNDING. National Cancer Institute (NCI), NIH grants R01CA172382, R01CA236780, R01CA261995, R01CA249279, and R50CA251961; US Army Medical Research and Development Command grants W81XWH2010137 and W81XWH-22-1-0082., Introduction Androgens and androgen receptor (AR) signaling are essential for normal prostate development, the initiation of prostate cancer, and tumor progression even at very advanced stages (1). Gonadal testosterone (T), [...]

Published
2023
Full Text
View/download PDF

33. Surgical Management and Oncologic Outcomes of Renal Cell Carcinoma and Inferior Vena Caval Thrombi With Aggressive Histologic Variants

Author

Lewis, Kevin C., primary, Werneburg, Glenn T., additional, Dewitt-Foy, Molly E., additional, Lundy, Scott D., additional, Eltemamy, Mohamed, additional, Murthy, Prithvi B., additional, Przybycin, Christopher G., additional, Campbell, Steven C., additional, Weight, Christopher, additional, and Krishnamurthi, Venkatesh, additional

Published
2023
Full Text
View/download PDF

39. The Deafening Silence of Male Infertility

Author

Nam, Catherine S., primary, Campbell, Kevin J., additional, Acquati, Chiara, additional, Bole, Raevti, additional, Adler, Ava, additional, Collins, David J., additional, Collins, Erica, additional, Samplaski, Mary, additional, Anderson-Bialis, Jake, additional, Andino, Juan J., additional, Asafu-Adjei, Denise, additional, Gaskins, Audrey J., additional, Bortoletto, Pietro, additional, Vij, Sarah C., additional, Orwig, Kyle E., additional, and Lundy, Scott D., additional

Published
2023
Full Text
View/download PDF

41. A Review of Combined Phosphodiesterase-5-Inhibitors and α-Blockers versus Phosphodiesterase-5-Inhibitors Alone for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia.

Author

Jackson, Elizabeth M, Khooblall, Prajit, Lundy, Scott D, and Bajic, Petar

Abstract

Guidelines from the American Urological Association (AUA) and the European Association of Urology (EAU) present conflicting recommendations regarding combination therapy of phosphodiesterase 5 inhibitors (PDE5is) with α-blockers to treat benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS). Use of PDE5is is widespread in the population of patients with LUTS/BPH. In this scoping review, we examine the evidence regarding the safety and efficacy of combined PDE5is and α-blockers compared to PDE5i medications alone. A search was conducted using PubMed, Cochrane, and Web of Science to identify manuscripts discussing the safety of PDE5i and α-blockers in combination or comparing this combination to PDE5is alone in the treatment of LUTS/BPH. Study designs, data, and conclusions were qualitatively analyzed. Combination therapy was found to be safe across all studies; importantly, no evidence documents increased risk of hypotension. Most studies reported added improvement in symptom and quality of life scores compared to PDE5i alone, with additional International Prostate Symptom Score (IPSS) change ranging from −1.30 to −8.50 and IPSS quality of life score change ranging from −0.15 to −1.50. Objective metrics such as postvoid residual volumes and maximum flow rate were inconsistently reported. Taken together, the current body of data suggests that combining PDE5i α-blocker therapy is safe and that there are opportunities for additional symptomatic improvement, though it should be utilized for select patients. Situations with particular utility could include patients with comorbid erectile dysfunction or without sufficient improvement on monotherapy. KEY POINTS combination therapy with PDE5i and α-blockers is more effective than PDE5i medications alone for lowering IPSS combination therapy with PDE5i and α-blockers is not associated with a significantly greater number of adverse events than PDE5i medications alone the improvements seen in IPSS with combination therapy compared to PDE5i alone may or may not reach the threshold of clinical significance PDE5i and α-blocker combination therapy should be considered a safe regimen that can be used in appropriate clinical situations, like for patients with comorbid ED and those who do not achieve sufficient control of symptoms with a daily PDE5i alone [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. AUTHOR REPLY

Author

Fascelli, Michele, primary, Lundy, Scott D., additional, Angermeier, Kenneth, additional, and Bajic, Petar, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results